Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
Related Posts
Albertsons Sues Kroger, Terminates Merger After Judge Blocks Supermarket Megadeal
Albertsons’ lawsuit said the rival grocery company failed to exercise its best efforts to win regulatory approval for the $20 billion deal.
Jeep Parent Stellantis Taking ‘Drastic Measures’ to Conserve Cash
The company’s finance chief revives “doghouse” requirements at global automaker to curb spending and reverse falling profit.
Basic Materials Roundup: Market Talk
Find insight on Hudbay Minerals, gold futures and more in the latest Market Talks covering Basic Materials.